N/A
Completed N=47
Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia
Source: ClinicalTrials.gov NCT03734822 ↗Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcomePrimary: Accuracy of CO2 Levels — 48.9; 39.5; 41.5; 44.3 mmHg
Summary
Four methods are routinely used to monitor CO2 in patients. End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia. CO2 is also monitored in other healthcare settings transcutaneously (TCO2), via finger stick capillary CO2 (CapCO2), and arterial blood gas (ABG). The purpose of this study is to perform all four measurements simultaneously during general anesthesia to identify which measure provides the most accurate data with the least amount of patient risk.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Accuracy of CO2 Levels |
48.9; 39.5; 41.5; 44.3 | — |
Eligibility Criteria
Inclusion Criteria
- Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value ≥ 60 mEq/L) and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype)
- Hemodynamically stable undergoing general anesthesia for a scheduled procedure
Exclusion Criteria
- Patients not diagnosed with CF
- CF patients undergoing anesthesia for emergency procedures
Data sourced from ClinicalTrials.gov (NCT03734822). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.